search
Back to results

Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity

Primary Purpose

Stroke, Brain Injuries, Spasticity

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Botox
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke focused on measuring Stroke, Brain Injuries, Spasticity, Botulinum Toxins

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria - Spasticity resulting from ABI (stroke, including vascular malformations, traumatic brain injury) Ashworth Score (resting) of at least 2 of the primary ankle plantarflexor (gastrocnemius) Onset of primary illness at least six months prior to study inclusion At least 12 years of age Exclusion Criteria - Hypersensitivity or allergy to botulinum toxin History of myasthenia gravis or other neuromuscular disease Current use of aminoglycosides Botulinum toxin or phenol injection to study limb within six months prior to recruitment Current use of other spasmolytic drug, such as diazepam, baclofen, dantrolene, tizanidine Presence of contracture or significant muscle atrophy Pregnancy

Sites / Locations

  • Kessler Institute for Rehabiliation
  • Memorial Hermann Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Other

Arm Label

1 - Low Volume, High Dose

2 - High Volume, High Dose

3 - High Volume, Low Dose

Arm Description

Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline

Botox (onabotulinumtoxinA), 150 units prepared as 50 units per 1 ml of preservative-free normal saline

Botox (onabotulinumtoxinA), 75 units prepared as 25 units per 1 ml of preservative-free normal saline

Outcomes

Primary Outcome Measures

Spastic Hypertonia as Measured by the Ashworth Scale
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0 - No increase in muscle tone - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension - More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed - Considerable increase in muscle tone, passive movement difficult - Limb in flexion or extension
Spastic Hypertonia as Measured by the Ashworth Scale
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension
Spastic Hypertonia as Measured by the Ashworth Scale
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension
Spastic Hypertonia as Measured by the Ashworth Scale
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension
Spastic Hypertonia as Measured by the Ashworth Scale
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension

Secondary Outcome Measures

Range of Motion as Measured by Goniometry
This outcome reports the angle formed during ankle dorsiflexion by an imaginary line drawn on the outer side of the leg with an imaginary line drawn on the outside of the foot. The angle changes as the ankle is curled up (dorsiflexed) or down (plantarflexed). Many people with stroke develop muscle tightness (a condition called spasticity) or contracture, which leads to ankle plantarflexion and results in a "foot drop" appearance and limits range of motion. When the ankle is neutral and the foot is flat, the angle between the leg and the foot is roughly a right angle, and this neutral position is indicated as 0 degrees from the neutral position. If the foot is below the neutral position during maximum ankle dorsiflexion, then the angle reported is the number of degrees below the neutral position (reported as a negative value). If the foot is above the neutral position, then the angle reported is the number of degrees above the neutral position (positive value).
Range of Motion as Measured by Goniometry
This outcome reports the angle formed during ankle dorsiflexion by an imaginary line drawn on the outer side of the leg with an imaginary line drawn on the outside of the foot. The angle changes as the ankle is curled up (dorsiflexed) or down (plantarflexed). Many people with stroke develop muscle tightness (a condition called spasticity) or contracture, which leads to ankle plantarflexion and results in a "foot drop" appearance and limits range of motion. When the ankle is neutral and the foot is flat, the angle between the leg and the foot is roughly a right angle, and this neutral position is indicated as 0 degrees from the neutral position. If the foot is below the neutral position during maximum ankle dorsiflexion, then the angle reported is the number of degrees below the neutral position (reported as a negative value). If the foot is above the neutral position, then the angle reported is the number of degrees above the neutral position (positive value).

Full Information

First Posted
September 12, 2005
Last Updated
January 4, 2021
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Allergan
search

1. Study Identification

Unique Protocol Identification Number
NCT00178646
Brief Title
Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
Official Title
Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 2002 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
March 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston
Collaborators
Allergan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.
Detailed Description
Spasticity is one of the most debilitating complications of neurologic conditions, such as stroke, brain injury, spinal cord injury, cerebral palsy, and multiple sclerosis. Although the exact pathophysiology is unknown, it is believed to result from an imbalance of ascending excitatory influences on and descending inhibitory components of the central nervous system. Clinically, spasticity manifests as abnormally increased muscle tone, associated with loss of range of motion, increased muscle stretch reflexes, clonus, weakness, and incoordination. If inadequately treated, spasticity leads to more disability and increase health care costs. Common complications of inadequately treated spasticity include joint and muscle contracture, pain, difficulty with performing activities of daily living and hygiene, and impaired transfers and ambulation. Acquired brain injuries (ABI), including stroke, traumatic brain injury, and encephalopathy, often lead to long-term impairments, including spasticity. In severe cases, spasticity is difficult and frustrating to treat in this patient population, since the individuals may not tolerate the side effects of conventional therapies because of ABI-related deficits in arousal and cognition. Systemic medications, such as baclofen and tizanidine, are effective in controlling spasticity; however, they may also cause sleepiness and drowsiness, and impair memory and thinking processes---adverse effects that individuals with ABI may not tolerate. Thus, "local" treatments, such as neurolysis and chemodenervation using botulinum toxin, have become superior treatment options in individuals with ABI, since they are devoid of the usual side effects of systemic medications. They are also effective in controlling spasticity, yet they do not impair arousal and cognition. The medical literature is replete with reports of the efficacy of botulinum toxin-A in the management of spasticity. Thus, the current challenge for clinicians and researchers at this time is to find ways to further enhance the efficacy of botulinum toxin. One way to achieve this is by exploiting certain properties of the toxin. Animal studies and clinical experience have shown that the effects of the drug is dose-dependent. One other property is the flexibility in preparing the volume of drug injected. Since botulinum toxin, as it is currently available (as BOTOX-A®) in the United States, requires reconstitution with preservative-free saline, there is flexibility for clinicians to manipulate the volume of solution that will be administered, without altering the dose. We recently completed a trial comparing the effects of two volume preparations of BOTOX-A® on wrist and finger flexor spasticity of individuals with ABI. One group of patients received BOTOX-A® prepared as 100 units/cc, while another received BOTOX-A® prepared as 50 units/cc. Although there was no statistically significant difference between the two groups, there was a trend in favor of the group that received the higher volume, i.e.; they appeared to improve more based on decrease in muscle tone (measured by the Modified Ashworth Scale). This was compared by the clinician's global impression that the high volume group improved more. The latter measure achieved statistical significance. One possible reason for the absence of statistical significance was that the "high" volume (50 units/cc) was not high enough. Thus, we are proposing this study to investigate the comparative effects of three preparations of BOTOX-A®.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Brain Injuries, Spasticity
Keywords
Stroke, Brain Injuries, Spasticity, Botulinum Toxins

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1 - Low Volume, High Dose
Arm Type
Experimental
Arm Description
Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline
Arm Title
2 - High Volume, High Dose
Arm Type
Active Comparator
Arm Description
Botox (onabotulinumtoxinA), 150 units prepared as 50 units per 1 ml of preservative-free normal saline
Arm Title
3 - High Volume, Low Dose
Arm Type
Other
Arm Description
Botox (onabotulinumtoxinA), 75 units prepared as 25 units per 1 ml of preservative-free normal saline
Intervention Type
Drug
Intervention Name(s)
Botox
Other Intervention Name(s)
generic name: botulinum toxin type A
Intervention Description
Botox 75-150 units, single treatment only
Primary Outcome Measure Information:
Title
Spastic Hypertonia as Measured by the Ashworth Scale
Description
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0 - No increase in muscle tone - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension - More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed - Considerable increase in muscle tone, passive movement difficult - Limb in flexion or extension
Time Frame
Baseline
Title
Spastic Hypertonia as Measured by the Ashworth Scale
Description
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension
Time Frame
Four weeks
Title
Spastic Hypertonia as Measured by the Ashworth Scale
Description
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension
Time Frame
Eight Weeks
Title
Spastic Hypertonia as Measured by the Ashworth Scale
Description
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension
Time Frame
Twelve Weeks
Title
Spastic Hypertonia as Measured by the Ashworth Scale
Description
The Ashworth Scale measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity. Score on the Ashworth scores ranges from 0-4, with 4 being the worst: 0: No increase in muscle tone Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension More marked increase in muscle tone through most of the range of motion, but affected limb easily flexed Considerable increase in muscle tone, passive movement difficult Limb in flexion or extension
Time Frame
Sixteen Weeks
Secondary Outcome Measure Information:
Title
Range of Motion as Measured by Goniometry
Description
This outcome reports the angle formed during ankle dorsiflexion by an imaginary line drawn on the outer side of the leg with an imaginary line drawn on the outside of the foot. The angle changes as the ankle is curled up (dorsiflexed) or down (plantarflexed). Many people with stroke develop muscle tightness (a condition called spasticity) or contracture, which leads to ankle plantarflexion and results in a "foot drop" appearance and limits range of motion. When the ankle is neutral and the foot is flat, the angle between the leg and the foot is roughly a right angle, and this neutral position is indicated as 0 degrees from the neutral position. If the foot is below the neutral position during maximum ankle dorsiflexion, then the angle reported is the number of degrees below the neutral position (reported as a negative value). If the foot is above the neutral position, then the angle reported is the number of degrees above the neutral position (positive value).
Time Frame
Baseline
Title
Range of Motion as Measured by Goniometry
Description
This outcome reports the angle formed during ankle dorsiflexion by an imaginary line drawn on the outer side of the leg with an imaginary line drawn on the outside of the foot. The angle changes as the ankle is curled up (dorsiflexed) or down (plantarflexed). Many people with stroke develop muscle tightness (a condition called spasticity) or contracture, which leads to ankle plantarflexion and results in a "foot drop" appearance and limits range of motion. When the ankle is neutral and the foot is flat, the angle between the leg and the foot is roughly a right angle, and this neutral position is indicated as 0 degrees from the neutral position. If the foot is below the neutral position during maximum ankle dorsiflexion, then the angle reported is the number of degrees below the neutral position (reported as a negative value). If the foot is above the neutral position, then the angle reported is the number of degrees above the neutral position (positive value).
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria - Spasticity resulting from ABI (stroke, including vascular malformations, traumatic brain injury) Ashworth Score (resting) of at least 2 of the primary ankle plantarflexor (gastrocnemius) Onset of primary illness at least six months prior to study inclusion At least 12 years of age Exclusion Criteria - Hypersensitivity or allergy to botulinum toxin History of myasthenia gravis or other neuromuscular disease Current use of aminoglycosides Botulinum toxin or phenol injection to study limb within six months prior to recruitment Current use of other spasmolytic drug, such as diazepam, baclofen, dantrolene, tizanidine Presence of contracture or significant muscle atrophy Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerard E Francisco, MD
Organizational Affiliation
University of Texas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kessler Institute for Rehabiliation
City
West Orange
State/Province
New Jersey
ZIP/Postal Code
07052
Country
United States
Facility Name
Memorial Hermann Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11964576
Citation
Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil. 2002 May;81(5):355-63. doi: 10.1097/00002060-200205000-00007.
Results Reference
background

Learn more about this trial

Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity

We'll reach out to this number within 24 hrs